Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 10/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368386 | 0.90 | CSNK1E (0.53) | CSNK1ENPC1RAB9AFAAHMAPT | |
| SCHEMBL13964365 | 0.88 | CSNK1E (0.54) | CSNK1ERAB9AFAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL13963912 | 0.88 | NPC1 (0.51) | CSNK1ENPC1RAB9AFAAHALDH1A1 | |
| SCHEMBL14368388 | 0.88 | CSNK1E (0.53) | CSNK1E | |
| SCHEMBL14368407 | 0.87 | NPC1 (0.50) | CSNK1ENPC1RAB9A | |
| SCHEMBL13964376 | 0.86 | CSNK1E (0.54) | CSNK1E | |
| SCHEMBL4043909 | 0.86 | CSNK1E (0.47) | CSNK1EFAAH | |
| SCHEMBL13964272 | 0.86 | CSNK1E (0.48) | CSNK1ENPC1RAB9AFAAHMAPT | |
| SCHEMBL14368415 | 0.85 | CSNK1E (0.49) | CSNK1EFAAH | |
| SCHEMBL13964198 | 0.84 | KDM4E (0.50) | CSNK1EFAAHMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CSNK1E 136/4885NPC1 1098/4885RAB9A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.